This week Microbot Medical launched the Liberty robot at the Society of Interventional Radiology conference, making endovascular robotics a commercial reality in the United States. At the same time, Medtronic is rolling out Hugo at academic medical centers, J&J’s Ottava is in FDA review, and Intuitive Surgical has cleared nine new cardiac surgery indications. Multiple markets are opening at the same time. That environment creates a specific kind of execution problem.
If You Are Building a Company in This Environment
When multiple adjacent markets open simultaneously, the instinct is to expand toward all of them. The endovascular space is moving. Cardiac is moving. Spine is moving. Ophthalmology is moving. There are potential customers in each of those segments, and each one looks like an opportunity. The founders who get in trouble are the ones who treat that as a mandate to chase all of it.
If you are building a company in this environment, whether you are developing an enabling device, a software layer, or a component that lives inside a robotic workflow, the single most important execution question right now is: which market are you actually building for? Not which markets could use your technology. Which specific clinical problem, in which specific care setting, with which specific evidence plan, are you going to finish before you do anything else.
This is the territory that Founders Who Finish covers. Not how to maximize optionality. How to make a clear choice about where to focus, execute against it with discipline, and build something that is actually done before you start the next thing.
Why Market Expansion Creates an Execution Trap
A market expansion is a fact about the world. A company strategy is a choice about where to deploy limited resources. The mistake founders make when they see a market expanding is treating the fact as the strategy. The endovascular category is opening up. That is true. It does not tell you whether you should be building for it, what the right entry point is, or what done looks like for your specific company.
The trap is this: a broadly defined opportunity attracts broadly defined effort. Teams build features for multiple potential segments, run pilots in multiple clinical environments, and pursue multiple regulatory pathways at the same time. Each of those activities is locally rational. But the compound effect is an organization that is present in many places and finished in none of them. That is how companies run out of runway before they have a product the market actually depends on.
Founders who finish make a different choice. They pick one clinical problem, define what a solved version of it looks like, and then build toward that definition without diverting. The market opportunity is background context. The specific problem is the target.
What the Execution Framework Looks Like in Practice
Founders Who Finish structures the execution problem around five questions that apply whether you are building a robotic system, an enabling device, or a software platform for any of the markets currently in motion.
Question 1
What are you actually finishing?
This is harder than it sounds. Most founders can describe their product. Fewer can describe the specific outcome that would constitute the product being done. For a medical device company, done might mean first-in-human data at two sites, a cleared indication, a reimbursement code, and three paying accounts. Whatever it is, it has to be specific enough that the whole organization knows what it is working toward and when you have arrived.
Question 2
Who decides you are done?
In most medical device companies, the answer involves a clinical champion, a procurement committee, a regulatory body, and a reimbursement pathway. Founders who finish map all of these before they start the work, because the path to done runs through each of them. Companies that discover a missing stakeholder late in the process are the ones that get stuck at the finish line after years of execution.
Question 3
What is the minimum evidence required to get there?
Every clinical market has an implicit evidence bar that governs whether accounts take you seriously. In endovascular procedures, that bar includes safety and procedural success data in a defined patient population. In cardiac surgery, it includes outcomes data at reference institutions. The founders who finish build toward that specific evidence requirement, not toward the maximum possible dataset. Scope creep in the clinical evidence plan is one of the most common ways medical device companies miss their funding window.
Question 4
What are you not doing?
The choices that matter most in a focused execution strategy are the ones you say no to. When the endovascular market opens while you are building for cardiac, the correct response is not to add an endovascular workstream. It is to note the development, assess whether it changes your strategy, and if not, return to the work you already committed to. The ability to say no to legitimate opportunities is what separates organizations that finish from organizations that are permanently almost done.
Question 5
What does the organization believe about finishing?
Execution discipline is a cultural property as much as a process one. Companies that consistently finish build the organizational belief that finishing is the job, not just building. That means celebrating shipped evidence, cleared indications, and signed accounts with the same energy that gets applied to product milestones. It means having hard conversations about scope early rather than late. And it means that the founder sets the expectation by finishing the things they personally commit to, every time.
The Long-Term Value of Finishing in a Fast-Moving Market
The surgical robotics and interventional device markets are moving faster than they have at any point in the past decade. That pace creates pressure to match the speed of the market by moving faster internally. But the companies that will matter in these markets five years from now are not the ones that chased the most opportunities. They are the ones that built deep clinical evidence and real commercial traction in a defined segment before they expanded. They finished something before they started the next thing.
That is the core argument of Founders Who Finish. Not that expansion is wrong. That finishing is what makes expansion possible. The reference account you built in endovascular procedures is what gets you into cardiac. The surgeon relationships you developed at three academic medical centers are what open the door to community hospitals. Scope and speed come after you have finished something worth referencing.
Founders Who Finish
The execution guide for founders building in regulated markets
If you are building a surgical device, an interventional platform, or enabling technology for a robotic workflow, this book is for the decisions you are making right now.
Get the Book